Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Roswell Park Comprehensive Cancer Center


Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

November 13, 2015

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.

Narrow Networks: Great Cancer Centers Need Not Apply

June 19, 2015

Insurance plans that limit which doctors have in-network status have become a mainstay of healthcare, helping keep costs down but stoking concerns and complaints from hospital administrators and regulators about patients' access to care.

Sequencing Puzzles in CRPC Therapies Remain Unsolved

January 23, 2014

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Dr. Adjei on Adverse Events From MEK Inhibitors

September 11, 2013

Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.

Dr. Wetzler Discusses the Use of Arsenic Trioxide in APL

March 26, 2013

Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, discusses a study presented at the 2012 American Society of Hematology Meeting analyzing arsenic trioxide in acute promyelocytic leukemia.